By Raetta Holdman

(CBS4) – More doses of the Pfizer and Moderna COVID-19 vaccine will be available as the CDC has told providers not to hold back the second doses. And two more vaccines are in the pipeline for approval.

(credit: CBS)

CBS4 Medical Editor Dr. Dave Hnida spoke in an interview on CBSN Denver this week about where we stand on the vaccine’s development. He says a single dose of the Pfizer vaccine offers about 50% protection, that number is 70% for the Moderna. And now AstraZeneca and Johnson & Johnson have vaccinations that could soon be administered.

READ MORE: Jefferson County Sheriff's Deputies Determine Suspicious Package At Clement Park Not A Threat

AstraZeneca’s vaccine is already being administered in parts of Europe.

“It is an effective vaccine, a two dose vaccine,” Hnida said. “It is inexpensive and very easy to produce. Those are very big pros in terms of that vaccine. … The problem with it, though, is some of the data — how much dosing to give has been a concern to regulators here in the United States.”

READ MORE: Jefferson County Parents, Students Protest Against Masks Policy For Schools
From one vial of the mock Covid-19 vaccines pharmacists will reconstitute the vaccine to create five doses per vial at Vail Health Hospital on December 8, 2020.

From one vial of the mock Covid-19 vaccines pharmacists will reconstitute the vaccine to create five doses per vial at Vail Health Hospital on December 8, 2020. (Photo by Helen H. Richardson/MediaNews Group/The Denver Post via Getty Images)

Hnida said he believes more information is needed before it is given emergency use authorization here.

And he calls the Johnson & Johnson vaccine a possible game changer.

“First off, it is a one dose vaccine. One (shot) and you’re done. It has a long shelf life. It can be administered after it sits in your state at an administration site for up to 3 months.”

MORE NEWS: COVID In Denver: Businesses Consider Proof Of Vaccination Status

“It does not require a lot of special handling. So hopefully this is a vaccine that will get an emergency use authorization in early March, then will wind up being distributed to the states.”

Raetta Holdman